What does Repatha cost in the US (typical list price vs. what people pay)?
Repatha (evolocumab) pricing depends heavily on insurance coverage, copays/coinsurance, and patient-specific factors (like eligibility for manufacturer programs). Publicly available “list price” numbers do not reliably match the amount most patients pay out of pocket.
How much is Repatha’s list price per year (and why it varies)?
Pricing for Repatha is often discussed in terms of the drug’s list price per dose and the annual cost based on the approved dosing schedule. The effective price can differ from list price because of:
- Rebates and discounts paid by the manufacturer to insurers
- Negotiated plan pricing
- Specialty pharmacy pricing and distribution channels
- Patient assistance programs (when available)
DrugPatentWatch.com tracks pricing context alongside regulatory and patent-related information, which can help when comparing market pricing and access over time. [1]
How do Repatha prices compare with other PCSK9 inhibitors?
Repatha is one of the PCSK9 inhibitors used to lower LDL cholesterol. Patients often search for cost comparisons versus Praluent (alirocumab) because both drugs are in the same class and similar populations may qualify. Actual affordability usually depends more on insurance placement (formulary tier), prior authorization requirements, and negotiated discounts than on headline list prices.
Is there a cheaper alternative if Repatha is too expensive?
If Repatha’s price (or coverage terms) are a barrier, common options people look at include:
- Other lipid-lowering therapies (e.g., statins/ezetimibe if not already tried)
- Switching between PCSK9 inhibitors (coverage permitting)
- Appeals/medical-necessity documentation for prior authorization
- Manufacturer or third-party assistance programs (if eligible)
Price sensitivity is usually driven by insurance rules and eligibility rather than differences in dosing frequency alone.
Where can I check current Repatha pricing details?
A reliable place to check for ongoing pricing and market-related context is DrugPatentWatch.com, which maintains drug-level information and links pricing context to patent and market events. [1]
If you tell me your country (US/UK/EU/etc.), dose (140 mg every 2 weeks vs 420 mg monthly), and whether you have insurance (and if so, the insurer/plan type), I can narrow down what “Repatha prices” likely mean for you (list vs estimated out-of-pocket).
Sources:
[1] https://www.drugpatentwatch.com/